VACCINE AREXVY OA VIAL + AS01E VIAL AU (RSV) 0.5ML

AREXVY is the first FDA-approved vaccine used to prevent lung and lower airway infection from respiratory syncytial virus (RSV) in people 60 years and older.

RSV is a respiratory virus that typically causes mild symptoms. However, RSV infections can be severe and dangerous for certain people.

In a clinical study, Arexvy was:

• over 82% effective in preventing lung and lower airway infection from RSV in people aged 60 years and older.
• over 94% effective in preventing lung and lower airway infection from RSV in people aged 60 years and older with asthma, diabetes, chronic obstructive pulmonary disease (COPD), chronic heart failure, advanced liver or kidney disease, or any chronic respiratory or pulmonary disease.